We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Lipitor Case Proves Strength Of Molecular Patents

Law360 (December 20, 2005, 12:00 AM EST) -- During Pfizer’s Inc.’s drawn out patent bout over blockbuster drug Lipitor, its long-time counsel Connolly Bove Lodge & Hutz LLP had a significant task that promised to affect an entire industry regardless of the outcome.

India-based generic drug maker Ranbaxy Laboratories took the unusual step of seeking to invalidate Lipitor’s molecular compound patent, the very heart of a drug’s intellectual property.

The daring attack, an attempt to break into Lipitor’s wild financial success as the world’s top-selling drug, has so far failed. That may bring a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.